In Brief
This article was originally published in The Tan Sheet
Executive Summary
NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning
You may also be interested in...
RCT Spells Requirement For Lipidryl, Shrinking Beauty Weight Loss Claims
Although FTC orders for RCTs to substantiate claims are criticized by some industry stakeholders, the agency routinely includes the burden of clinical trials in settlements with firms found to conduct false and misleading advertising for consumer health products, particularly in the weight loss area.
RCT Spells Requirement For Lipidryl, Shrinking Beauty Weight Loss Claims
Although FTC orders for RCTs to substantiate claims are criticized by some industry stakeholders, the agency routinely includes the burden of clinical trials in settlements with firms found to conduct false and misleading advertising for consumer health products, particularly in the weight loss area.
DermaTend Firm Faces Re-Labeling To Keep Lotions On Market
Solace International’s recall announcement notes that “DermaTend is not FDA-approved,” and “using these DermaTend products instead of seeking medical attention could result in delayed diagnosis of conditions such as cancer.”